Proteins are the machines our bodies run on, and predicting how they interact is central to designing new treatments. In the wake of AlphaFold’s 2024 Nobel win, what’s the state of AI models for proteins, and how do techbio business models impact which scientists can use them?
I recently sat down with
@GabriCorso, CEO and co-founder of
@boltz_bio, a venture-backed startup driven by opening up scientist access to these models.
In our conversation we covered:
The shift from discovering drugs by chance to designing them with AI models (Boltz-1, Boltz-2, and BoltzGen)
Boltz's focus on openness, and how it diverges from fully integrated efforts like DeepMind's Isomorphic Labs
Boltz’s multi-year partnership with
@pfizer, and how proprietary data sharpens models for a company's specific drug-discovery efforts
The road to "zero-shot drugs," autonomous labs, and the future of bio R&D
If you're curious about where frontier AI meets drug discovery, check out this latest episode of the Discovery Engines Podcast.
👀 YouTube:
youtu.be/fLY5yhRNEKg
🎧 Spotify:
open.spotify.com/episode/50K…